Ewing's sarcoma in scapula, epidemiology, clinical manifestation, diagnosis and treatment: A literature review

Shashaa, Mohammad Nour; Alkarrash, Mohamad Shadi; Kitaz, Mohammad Nour; Hawash, Shahd; Otaqy, Mohammad Baraa; Tarabishi, Joudi; Rhayim, Roaa; Alloush, Hani

doi:10.1016/j.amsu.2022.103617

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of metastatic bone disease has been the subject of many advances in medical and surgical treatments over the past few decades, however, the treatment of scapular lesions poses a serious challenge, due to the complex skeletal and neurovascular structures involved [3,[12][13][14]. In our series, all patients were not candidate for surgical intervention due to limited life expectancy and the high risk for damage to neurovascular structures.…”

Section: Discussionmentioning

confidence: 96%

Efficacy and Safety of Arterial Embolization for Scapular Metastases

Papalexis,

Peta,

Marinelli

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: To investigate the safety and efficacy of palliative arterial embolization for metastases of the scapula. Materials and Methods: We studied the files of the patients who underwent palliatrive arterial embolization for metastases of the scapula from January 2016 to January 2023, 15 patients (8 M, and 7 F) with a mean age of 62 years (SD 10.2) with two patients receiving a second procedure, for a total of 17 embolizations. Data on technical and clinical success, as well as changes in tumor size, were collected. All embolization-related complications were evaluated according to the CIRSE classification system for complications. Results: The average follow-up was 18 months (Range 6-36 months). The main primary tumor were renal, lung and breast cancer. The primary arteries embolized were the circumflex scapular artery, the dorsal scapular artery, and the thoracoacromial trunk. A mixture of Glubran and Lipiodol in a 1:2 ratio was used for embolization, with an average of 1.1 mL (Range 0.5-1.5 mL) used per procedure. The efficacy of embolization was measured using the Visual Analogue Scale (VAS), with values recorded at baseline, at 1, 3, 6, and 12 months post-embolization, and at 6-month intervals after. Baseline VAS scores averaged 7.2 (SD 1.5), decreasing to 2.8 (SD 0.9) at one month. Progressive reduction was observed at 3, 6, and 12 months with scores of 2.3 (SD 0.8), 1.9 (SD 0.7), and 1.6 (SD 0.6) respectively. Metastatic tumor size was reduced from a mean of 192.2 cm3 (range 38.7 to 480.1 cm3) pre-embolization to a mean of 177.3 cm3 (range 37.2 to 455.5 cm3) at the 12-month follow-up (p

show abstract

Section: Discussionmentioning

confidence: 96%